Amgen says obesity drug caused up to 20% weight loss

New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated readout sent the company’s shares tumbling.
Amgen’s stock closes off lows to avoid worst day in 24 years as weight-loss-drug data underwhelms
Amgen Inc.’s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year,
Wall Street awaits Amgen weight-loss drug data expected to move shares
Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo Nordisk .
Amgen shows 20% weight loss in once-monthly injectable MariTide
Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.
Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.
Amgen stock was dropping in premarket trading after releasing data from a Phase 2 study for its experimental weight-loss drug, MariTide. The pharmaceutical company said in a statement that after 52 weeks,
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.
Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study
Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart cafraglutide, formerly AMG 133 -, an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently.
Amgen weight loss data ‘underwhelms,’ says Deutsche Bank
MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight loss appears to miss the Street’s bogey of 25% weight loss and will weigh down Amgen shares,
Amgen Drug Delivers More Weight Loss Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Daily1d
Maritide effects robust weight loss in people living with obesity or overweight at 52 weeks in a phase 2 study
According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...
MM&M5d
Amgen’s MariTide achieves 20% weight loss, but Wall Street remains unimpressed
Amgen released the long-awaited results from its study of weight loss injection MariTide and the results — while ...